List view / Grid view
Hal V. Barron (born 1962) is an American clinician-scientist and drug developer currently serving as president of research and development at Calico. He has served as executive vice president, head of global product development, and chief medical officer of Hoffman-La Roche.
Barron joined Genentech in 1996 as a clinical scientist and was promoted in 2002 to Vice President of Medical Affairs. In 2002 Barron was promoted to vice president of medical affairs and in 2003 he became the senior vice president of development. In 2004 he was appointed chief medical officer and in 2009 he was appointed executive vice president.
Barron’s current academic positions at the University of California, San Francisco include Associate Adjunct Professor of Epidemiology and Biostatistics, and Associate Clinical Professor of Medicine/Cardiology. He has been issued several patents for his work in thrombosis and angiogenesis, and has published more than 90 papers in peer-reviewed scientific journals. He was a member of the board of directors at Alexza Pharmaceuticals.
Roche announced topline results of its first randomized trial of…
7 April 2011 | By Roche
Roche announced topline results of its first randomized trial of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer...
Roche today announced that a pivotal Phase II clinical study…
21 March 2011 | By Roche
Roche today announced that a pivotal Phase II clinical study of its investigational Hedgehog Pathway Inhibitor, vismodegib (RG3616/GDC-0449), showed positive results...
Avastin in combination with paclitaxel will remain a treatment option…
2 March 2011 | By Roche
Avastin in combination with paclitaxel will remain a treatment option for women with metastatic breast cancer in Europe...
Roche announced that the U.S. FDA approved Rituxan/MabThera as a…
31 January 2011 | By Roche
Roche announced that the U.S. FDA approved Rituxan/MabThera as a maintenance treatment for patients with advanced follicular lymphoma...
Roche today presented eight-week results from a phase II study…
6 December 2010 | By F. Hoffmann-La Roche Ltd
Roche today presented eight-week results from a phase II study of RG16781...
